Zobrazeno 1 - 10
of 20
pro vyhledávání: '"TGI, tumor growth inhibition"'
Autor:
Zhang Zhang, Sihua Zhu, Qian Li, Sanfang Tu, Ke Ding, Liang Jiang, Zhengchao Tu, Yuting Wang, Xiaoyun Lu
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 5, Pp 1315-1328 (2021)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
Bcr-Abl threonine 315 to isoleucine 315 (T315I) gatekeeper mutation induced drug resistance remains an unmet clinical challenge for the treatment of chronic myeloid leukemia (CML). Chemical degradation of Bcr-AblT315I protein has become a potential s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46d7e646ae40d932bccd80bff158248
http://www.sciencedirect.com/science/article/pii/S2211383520307991
http://www.sciencedirect.com/science/article/pii/S2211383520307991
Autor:
Wenfu Tan, Huaqian Ding, Xiaohua Liu, Chunyong Ding, Juan Wang, Yalei Li, Ao Zhang, Yu Zhang, Hongchun Liu, Wenjing Huang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 2, Pp 488-504 (2021)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
Medulloblastoma (MB) is a common yet highly heterogeneous childhood malignant brain tumor, however, clinically effective molecular targeted therapy is lacking. Modulation of hedgehog (HH) signaling by epigenetically targeting the transcriptional fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301cde2b3eb755a22e93dd5c8eb925b1
https://doi.org/10.1016/j.apsb.2020.07.007
https://doi.org/10.1016/j.apsb.2020.07.007
Autor:
Zhuowei Liu, Yuxi Wang, Chengjian Zhao, Yang Zhang, Manyu Zhao, Jinliang Yang, Yuqin Yao, Peng Li, Chen Zhengxia, Xiaoxin Chen, Chaofeng Long
Publikováno v:
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica B, Vol 10, Iss 8, Pp 1453-1475 (2020)
Acta Pharmaceutica Sinica B, Vol 10, Iss 8, Pp 1453-1475 (2020)
Angiokinases, such as vascular endothelial-, fibroblast- and platelet-derived growth factor receptors (VEGFRs, FGFRs and PDGFRs) play crucial roles in tumor angiogenesis. Anti-angiogenesis therapy using multi-angiokinase inhibitor has achieved great
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a6380c470a4be26e380966eab21f579
http://europepmc.org/articles/PMC7488503
http://europepmc.org/articles/PMC7488503
Autor:
Xingxing Yang, Vitalii Zablotskii, Biao Yu, Chao Song, Xin Zhang, Junjun Wang, Xin Yu, Lei Zhang
Publikováno v:
Translational Oncology, Vol 14, Iss 7, Pp 101103-(2021)
Translational Oncology
Translational Oncology
Highlights • Upward 9.4 T SMF exposure for 88 h significantly inhibited A549 tumor growth in mice. • 9.4 T SMF treatment for 88 h had no severe impairment to the mice key organs or blood cell count. • Upward 9.4 T SMF treatment for 24 h caused
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e7864349eb421a0aa88d38281c5dfa2
http://www.sciencedirect.com/science/article/pii/S1936523321000954
http://www.sciencedirect.com/science/article/pii/S1936523321000954
Autor:
Thomas Valerius, Paul W. H. I. Parren, Janine Schuurman, Joost J. Neijssen, William R. Strohl, Kristen M. Chevalier, Luus Wiegman, Cardoso Rosa Maria Fernandes, Mark L. Chiu, Sheri Moores, G. Mark Anderson
Publikováno v:
The Journal of Biological Chemistry
Journal of Biological Chemistry, 296. ELSEVIER
Journal of Biological Chemistry, 296. ELSEVIER
A bispecific antibody (BsAb) targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways represents a novel approach to overcome resistance to targeted therapies in patients with nonsmall cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca933b2c86ba6635402921bd327c1a34
https://hdl.handle.net/1887/3256851
https://hdl.handle.net/1887/3256851
Autor:
Wan-Jian Gu, Jingyu Liu, Xiaoyu Ding, Xiaoyao Hao, Lan Luo, Yujie Zhong, Mingjiu Chen, Shukai Xia, Chunni Zhang
Publikováno v:
EBioMedicine, Vol 60, Iss, Pp 102996-(2020)
EBioMedicine
EBioMedicine
Background: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648cd0a265f6e18629465a76cccea959
http://www.sciencedirect.com/science/article/pii/S2352396420303728
http://www.sciencedirect.com/science/article/pii/S2352396420303728
Autor:
Aiwen Wu, Xiao-Yan Zhang, Zhongwu Li, Shuai Wang, Lin Wang, Yingjie Li, Yiyou Chen, Tingting Sun, Yihong Zhang, Dagang Guo
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100935-(2021)
Translational Oncology
Translational Oncology
Highlights • Established a new in vitro tumor model called novel conditionally reprogrammed (termed i-CR). • Accomplished personalized drug tests within 2–3 weeks. • Achieved 100% sensitivity, 85.7% specificity, 91.7% positive predictive valu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273f00fde56c8ec0741f9a7e4df7bbc3
https://doi.org/10.21203/rs.3.rs-35145/v1
https://doi.org/10.21203/rs.3.rs-35145/v1
Autor:
Xiaosa, Chang, Dejuan, Sun, Danfeng, Shi, Guan, Wang, Yanmei, Chen, Kai, Zhang, Huidan, Tan, Jie, Liu, Bo, Liu, Liang, Ouyang
Publikováno v:
Acta Pharmaceutica Sinica. B
This study was aimed to design the first dual-target small-molecule inhibitor co-targeting poly (ADP-ribose) polymerase-1 (PARP1) and bromodomain containing protein 4 (BRD4), which had important cross relation in the global network of breast cancer,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::104d38c88984daa177c12922a724ee12
https://pubmed.ncbi.nlm.nih.gov/33532187
https://pubmed.ncbi.nlm.nih.gov/33532187
Autor:
Martinez-Cruzado, Lucia, Tornin, Juan, Rodriguez, Aida, Santos, Laura, Allonca, Eva, Fernandez-Garcia, Maria Teresa, Astudillo, Aurora, Garcia-Pedrero, Juana Maria, Rodriguez, Rene
Publikováno v:
Neoplasia (New York, N.Y.)
Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::85aa599e58a91e1a98cce0f0d21e994f
http://europepmc.org/articles/PMC5421973
http://europepmc.org/articles/PMC5421973
Autor:
Douglas Buckley, Timothy S. Heuer, Julie Lai, George Kemble, Kasia Mordec, Richard Benn Abegania Ventura, Marina Fridlib
Publikováno v:
EBioMedicine, Vol 16, Iss C, Pp 51-62 (2017)
EBioMedicine
EBioMedicine
Palmitate, the enzymatic product of FASN, and palmitate-derived lipids support cell metabolism, membrane architecture, protein localization, and intracellular signaling. Tubulins are among many proteins that are modified post-translationally by acyla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a802f596b8c80bcd58cda8b58cc926
http://www.sciencedirect.com/science/article/pii/S2352396416305916
http://www.sciencedirect.com/science/article/pii/S2352396416305916